Camrelizumab and metronomic capecitabine for patients with treatment-refractory solid tumors (McCREST trial).
Sign Up to like & getrecommendations! Published in 2022 at "Future oncology"
DOI: 10.2217/fon-2021-1579
Abstract: This is an open-label, single-center, multi-cohort phase Ib trial, which consists of three cohorts, including cohort 1 (HER2 negative gastric or gastric esophageal junction adenocarcinoma), cohort 2 (esophageal squamous cell carcinoma and head and neck squamous… read more here.
Keywords: metronomic capecitabine; capecitabine patients; trial; camrelizumab metronomic ... See more keywords